ClinicalTrials.gg
RecruitingNCT06119490TENUpdated Nov 28, 2023

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

An Early Phase 1 interventional study of Abrocitinib and Tofacitinib in Toxic Epidermal Necrolysis, sponsored by Peng Zhang. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Peng Zhang · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Jul 2023, registered Oct 2023).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

02

Conditions studied

  • Toxic Epidermal Necrolysis
03

In context

Stevens-Johnson Syndrome

40 studies on the registry are indexed under Stevens-Johnson Syndrome; 8 are open to participants now.

This study's planned enrollment of 30 is above the median of 20 across 24 interventional studies indexed under Stevens-Johnson Syndrome.

Browse Stevens-Johnson Syndrome studies →

Lead sponsor

Peng Zhang is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 and above.
  2. Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
  3. Liver and kidney function is within acceptable ranges.
  4. Blood parameters, including complete blood count, coagulation function, and count, are within acceptable ranges.
  5. Patients must sign an form, understanding the risks and potential benefits of the treatment.
  6. Patients need to be capable of participating in follow-up visits and treatment plans.

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to JAK inhibitors.
  2. Pregnant or breastfeeding women.
  3. Severe infectious conditions.
  4. History of central nervous system demyelinating diseases.
  5. History of lymphoproliferative diseases.
  6. Active and latent tuberculosis.
  7. carriers with a lower than (\<200/mL).
  8. Active / infection.
  9. Coagulation disorders or a tendency for thrombosis.
  10. Significant abnormalities in blood routine indicators.
  11. Liver or kidney dysfunction.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Arocitinib-arm

    Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with Arocitinib 200 mg daily.

    Drug: Abrocitinib

  • Other
    Tofacitinib-arm

    Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with tofacitinib 10 mg daily.

    Drug: Tofacitinib

Interventions

  • Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Arocitinib tablets 200 mg per day for 2 weeks

    Also known as: Solu-Medrol®

  • Solu-Medrol® 1 mg/kg body weight intravenous infusion per day in combination with Tofacitinib tablets 10 mg per day for 2 weeks

    Also known as: Solu-Medrol®

06

What researchers measure

Primary outcomes

  1. Time to Reepithelization

    duration from initiation of treatment to the point when skin detachment and erosions were no longer observed (negative Nikolsky's sign). Meanwhile, skin islands started to regenerate and replace the damaged superficial epithelia in local skin or mucous lesions (approximately 20% of the maximum BSA).

    Time frame: up to 8 week

Secondary outcomes

  1. Adverse events

    The common adverse effects associated with treatments including elevated blood pressure, elevated blood glucose, gastrointestinal bleeding, electrolyte disturbance, and mucocutaneous infections were closely monitored during their hospitalization. All patients in both groups were followed up for 4 weeks to monitor the associated adverse effects.

    Time frame: up to 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Dermatology, the First Affiliated Hospital of Fujian Medical University.
    Fuzhou, Fujian 350000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The results will be published in a peer-reviewed scientific paper and the data sets analyzed in this study can be obtained from the first author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Jul 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 7, 2023
StartActual
Jul 5, 2023
Primary completionEst.
Jul 2026
CompletionEst.
Sep 2026
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06119490
Lead sponsor
Peng Zhang
Responsible party
Peng Zhang (Investigator, Fujian Provincial Hospital) — Sponsor-investigator
First posted
Nov 7, 2023
Start date
Jul 5, 2023
Primary completion
Jul 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Nov 28, 2023

Study contacts

Chao Ji
Contact
jichaofy@fjmu.edu.cn
+86 18651619908
Peng Zhang
Contact
396159837@qq.com
+86 13645096437

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abrocitinib · Tofacitinib

Start the discussion